Japan-based pharma Eisai and its US partner Biogen, which has a large campus in RTP, could receive full FDA approval for their Alzheimer’s drug by July 6, the companies announced Monday.
Read More
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Here’s what is happening.
Read More
An experimental Alzheimer’s drug from Biogen and partner Eisai modestly slowed the brain disease’s inevitable worsening, researchers report – but it remains unclear how much difference that might make in people’s lives.
Read More
